International Assets Investment Management LLC Purchases 35,937 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

International Assets Investment Management LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5,623.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,576 shares of the biopharmaceutical company's stock after purchasing an additional 35,937 shares during the period. International Assets Investment Management LLC's holdings in Halozyme Therapeutics were worth $20,940,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. TD Asset Management Inc raised its stake in shares of Halozyme Therapeutics by 28.1% in the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company's stock valued at $103,379,000 after acquiring an additional 557,350 shares in the last quarter. Handelsbanken Fonder AB raised its stake in shares of Halozyme Therapeutics by 76.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock valued at $112,715,000 after acquiring an additional 856,200 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock valued at $99,363,000 after acquiring an additional 209,530 shares in the last quarter. Epoch Investment Partners Inc. raised its stake in shares of Halozyme Therapeutics by 23.3% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company's stock valued at $58,319,000 after acquiring an additional 270,579 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Halozyme Therapeutics by 9.7% in the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company's stock valued at $43,002,000 after acquiring an additional 72,544 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on HALO shares. Benchmark reaffirmed a "buy" rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Wells Fargo & Company downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their price target for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. HC Wainwright reaffirmed a "buy" rating and issued a $65.00 price target on shares of Halozyme Therapeutics in a research report on Friday, October 25th. Finally, The Goldman Sachs Group lifted their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a "neutral" rating in a research report on Monday, July 22nd. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $60.44.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company's stock, valued at approximately $40,063,244.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 9,881 shares of the business's stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the transaction, the director now owns 69,874 shares of the company's stock, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Helen Torley sold 10,000 shares of the business's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $40,063,244.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 89,881 shares of company stock valued at $5,169,834 in the last 90 days. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Price Performance

HALO stock traded up $0.12 during trading on Wednesday, hitting $50.76. The company had a trading volume of 231,968 shares, compared to its average volume of 1,270,028. The company has a fifty day moving average price of $57.56 and a two-hundred day moving average price of $51.83. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. The company has a market cap of $6.46 billion, a P/E ratio of 20.93, a P/E/G ratio of 0.50 and a beta of 1.27. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.07 and a fifty-two week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.73 by $0.18. The business had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. Halozyme Therapeutics's quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.68 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.